TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial

TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial

BackgroundThe high recurrence rate of hepatocellular carcinoma (HCC) after surgery negatively affects the prognosis of patients. There is currently no widely accepted adjuvant therapy strategy for patients with HCC. A clinical study of effective adjuvant therapy is still needed.MethodsIn this prospe...

Full description

Bibliographic Details
Main Authors: Weili Qi, Wei Peng, Xin Qi, Zhancheng Qiu, Tianfu Wen, Chuan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
adjuvant therapy
VEGF
PD-1
TACE
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1138570/full

Similar Items

Similar Items